Related Experiment Video

Updated: Sep 13, 2025

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.4K

Alzheimer's Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective

Naomi Scarano1,2, Francesca Musumeci1, Beatrice Casini1,2

  • 1Department of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV, 3, 16132 Genoa, Italy.

International Journal of Molecular Sciences
|July 29, 2025
PubMed

Insights

Alzheimer's disease (AD) treatments offer symptomatic relief but don't address the cause. Understanding neuroprotective genes is key for developing effective Alzheimer's disease prevention and precision medicine strategies.

Area of Science:

  • Neurodegenerative disease research
  • Genetics and Alzheimer's disease
  • Pharmacology and therapeutic strategies

Background:

  • Alzheimer's disease (AD) is a leading cause of dementia, characterized by progressive neurodegeneration.
  • Current therapies offer only symptomatic relief, failing to address AD pathogenesis.
  • Clarifying AD etiology and enhancing neuroprotection are critical for effective interventions.

Purpose of the Study:

  • To review the physiological aspects and risk factors of Alzheimer's disease.
  • To analyze current therapeutic approaches, including neurotransmitter modulation, peptide deposit control, and non-specific treatments.
  • To explore innovative strategies and non-pharmaceutical support for AD management.

Main Methods:

  • Literature review focusing on Alzheimer's disease pathophysiology and treatment.
  • Categorization of therapeutic strategies into neurotransmitter/ion modulation, peptide deposit control, and aspecific treatments.
  • Discussion of current treatment limitations and future directions.

Main Results:

  • Approved AD therapies provide symptomatic benefits but do not halt disease progression.
  • Understanding gene-specific neuroprotective mechanisms is essential for novel drug development.
  • Limitations in current treatments highlight the need for innovative and personalized approaches.

Conclusions:

  • Effective Alzheimer's disease management requires a shift towards prevention and etiological understanding.
  • Precision medicine and targeted therapies hold promise for future AD treatment.
  • Integrating innovative strategies and ancillary support may improve patient outcomes.
Keywords:
Alzheimer’s diseaseFDA approved drugsnon-pharmacological treatmentspreventionrisk factorstherapeutics strategies

More Related Videos

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.4K
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
166
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
967
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.9K